United States Drug Patent 8,291,904: Analysis of Scope, Claims, and Landscape
Summary: United States Patent 8,291,904, titled "Method of treating depression," issued on October 18, 2012, to Lundbeck Research USA, Inc. The patent claims methods of treating major depressive disorder (MDD) by administering a specific dosage range of vortioxetine, a selective serotonin reuptake enhancer and 5-HT3 antagonist. The patent landscape surrounding vortioxetine is characterized by a primary composition of matter patent and subsequent method of use and formulation patents, with ongoing litigation and patent expirations influencing market exclusivity.
What is the Core Invention Claimed by US Patent 8,291,904?
Patent 8,291,904 claims a method for treating major depressive disorder. Specifically, it covers administering vortioxetine in a daily dose ranging from 5 mg to 20 mg. The patent defines MDD as a depressive episode that has lasted for at least two weeks, with specified diagnostic criteria, and outlines methods for patient selection based on symptom severity.
The primary objective of the invention is to provide an effective and well-tolerated treatment regimen for MDD. The patent emphasizes the efficacy of vortioxetine within this specific dosage range, particularly in relation to its multimodal mechanism of action. This mechanism involves the inhibition of serotonin (5-HT) reuptake, as well as direct modulation of several serotonin receptors, including 5-HT1A agonism, 5-HT1B partial agonism, 5-HT3 antagonism, 5-HT1D antagonism, and 5-HT7 antagonism.
The patent details specific examples of the method, including initiating treatment with a 10 mg daily dose and adjusting to 5 mg or 20 mg based on patient response and tolerability. It also describes patient populations that may benefit from this method, such as those with recurrent MDD or patients who have not responded adequately to previous antidepressant treatments.
What are the Specific Claims of US Patent 8,291,904?
The patent contains several claims, with Claim 1 being the broadest method of treatment claim.
- Claim 1: A method of treating major depressive disorder in a patient, comprising administering to the patient a daily dose of vortioxetine of from 5 mg to 20 mg.
- Claim 2: The method of claim 1, wherein the daily dose is 10 mg.
- Claim 3: The method of claim 1, wherein the daily dose is 20 mg.
- Claim 4: The method of claim 1, wherein the daily dose is 5 mg.
- Claim 5: The method of claim 1, wherein the patient has a recurrent major depressive disorder.
- Claim 6: The method of claim 1, wherein the patient has failed to respond to previous antidepressant treatment.
- Claim 7: The method of claim 1, wherein the vortioxetine is administered as a single daily dose.
- Claim 8: The method of claim 1, wherein the vortioxetine is administered orally.
- Claim 9: The method of claim 1, wherein the vortioxetine is administered in the form of a tablet or capsule.
- Claim 10: The method of claim 1, wherein the vortioxetine is formulated with at least one pharmaceutically acceptable excipient.
- Claim 11: The method of claim 1, wherein the vortioxetine is administered in combination with another antidepressant drug.
- Claim 12: The method of claim 1, wherein the vortioxetine is administered in combination with an adjunctive therapy.
- Claim 13: The method of claim 1, wherein the patient is selected based on the severity of their depressive symptoms.
- Claim 14: The method of claim 13, wherein the severity of depressive symptoms is assessed using a recognized rating scale for depression.
- Claim 15: The method of claim 1, wherein the vortioxetine is administered for at least 6 weeks.
These claims define the specific therapeutic context and dosage parameters for vortioxetine in treating MDD, establishing a basis for market exclusivity for this particular treatment regimen.
What is the Relationship Between US Patent 8,291,904 and the Composition of Matter Patent for Vortioxetine?
US Patent 8,291,904 is a method of use patent that builds upon the foundational composition of matter patent for vortioxetine. The composition of matter patent, typically the earliest and broadest patent for a novel drug substance, protects the chemical entity itself. For vortioxetine, the primary composition of matter patent is generally understood to be related to patents held by Lundbeck A/S, such as US Patent 7,776,907, which claims vortioxetine and its salts.
US Patent 8,291,904, granted later, specifically claims the method of using vortioxetine within a defined dosage range for treating MDD. This is a common strategy in pharmaceutical patenting to extend market exclusivity beyond the expiration of the original composition of matter patent. Method of use patents protect a specific therapeutic application, allowing the patent holder to prevent others from practicing that particular method, even if the drug itself is off-patent or protected by a different patent.
The distinction is crucial: the composition of matter patent prevents the manufacture and sale of vortioxetine itself, while US Patent 8,291,904 prevents others from marketing and prescribing vortioxetine for the treatment of MDD within the specified dosage range.
What is the Exclusivity Period of US Patent 8,291,904?
US Patent 8,291,904 was granted on October 18, 2012. Under U.S. patent law, the term of a utility patent is generally 20 years from the date on which the application was filed. However, various extensions and adjustments can apply.
Assuming a filing date of approximately 2002-2003 (typical for a patent issued in 2012), the initial term would have expired around 2022-2023. Pharmaceutical patents are also eligible for Patent Term Adjustment (PTA) and Patent Term Extension (PTE) to compensate for delays in the patent office and regulatory review.
Specifically for vortioxetine (marketed as Trintellix/Brintellix), the U.S. Food and Drug Administration (FDA) Orange Book lists multiple patents covering the drug. The listed patents for vortioxetine, including those related to composition of matter, methods of use, and formulations, have varying expiration dates. For instance, patents related to the initial composition of matter or specific early uses might have expired earlier, while method of use patents like 8,291,904, or later formulation patents, could have extended exclusivity.
Based on publicly available information and typical patent lifecycles for drugs approved in the early 2010s, the exclusivity period for patent 8,291,904, without considering any specific extensions or challenges, would have ended in the early to mid-2020s. However, the actual market exclusivity is influenced by the interplay of all granted patents and potential litigation outcomes.
How Does the Patent Landscape for Vortioxetine Affect Market Competition?
The patent landscape for vortioxetine, including US Patent 8,291,904, dictates the timeline for generic competition. The presence of multiple patents covering different aspects of the drug—composition of matter, specific methods of treatment, and formulations—allows the innovator company (Lundbeck and Takeda for the U.S. market) to maintain market exclusivity for extended periods.
- Composition of Matter Patents: These provide the most fundamental protection, preventing any unauthorized synthesis or sale of the active pharmaceutical ingredient (API).
- Method of Use Patents (like 8,291,904): These protect specific therapeutic applications. Even after the composition patent expires, method patents can prevent generic manufacturers from marketing their drug for the protected indication using the patented method or dosage. This forces generic companies to seek approval for different uses or to challenge the validity of the method patent.
- Formulation Patents: These protect specific ways the drug is prepared or delivered, such as extended-release formulations or specific excipient combinations. These can also extend exclusivity.
The expiration of key patents, including method of use patents, is the primary trigger for generic drug entry. Once all relevant patents have expired or been invalidated, generic manufacturers can submit Abbreviated New Drug Applications (ANDAs) to the FDA. The FDA's approval of an ANDA permits the marketing of a generic version of the drug, typically leading to significant price reductions and increased market access.
Litigation plays a critical role. Generic companies often challenge the validity or inventiveness of innovator patents. Successful challenges can lead to earlier generic entry. Conversely, patent holders may sue generic manufacturers for infringement, seeking to delay generic competition. The outcome of these legal battles directly shapes the competitive landscape.
For vortioxetine, the patent landscape has been subject to litigation, with generic companies seeking to invalidate or design around existing patents to facilitate market entry. The expiration of patents, combined with successful patent challenges or settlements, ultimately determines when generic versions become available.
What is the Litigation History Related to Vortioxetine Patents?
The patent portfolio for vortioxetine, including patents like US 8,291,904, has been the subject of significant patent litigation. This is typical for successful branded pharmaceuticals as their patent exclusivity nears expiration. Generic manufacturers frequently challenge the validity of these patents or argue that their proposed generic products do not infringe.
Key aspects of vortioxetine patent litigation typically involve:
- Challenges to Method of Use Patents: Generic companies often target method of use patents, arguing they are either invalid (e.g., obvious, not novel) or that their proposed generic product and prescribing information do not infringe. For instance, generic labels might omit mention of a patented indication or dosage.
- Infringement Lawsuits: The innovator companies (Lundbeck and Takeda) have historically filed lawsuits against generic manufacturers who file ANDAs for vortioxetine, alleging infringement of their patents.
- Patent Term Extension (PTE) and Patent Term Adjustment (PTA) Disputes: Litigation can also arise over the calculation of patent terms, particularly concerning extensions granted to compensate for FDA review delays.
- "Paragraph IV" Filings: Under the Hatch-Waxman Act, generic companies can file an ANDA by certifying that the relevant patents are invalid, unenforceable, or will not be infringed (a "Paragraph IV certification"). This often triggers a 30-month stay of FDA approval while patent litigation is resolved, or it can lead to immediate litigation if the patent holder sues for infringement.
Specific legal actions against vortioxetine patents have involved multiple generic pharmaceutical companies, including Teva Pharmaceuticals, Mylan, and others. These cases often revolve around the claims of patents covering the drug itself, specific therapeutic uses, and manufacturing processes or formulations. The outcomes of these litigations have a direct impact on the timing of generic market entry for vortioxetine. For example, successful challenges to key patents can accelerate generic availability, while successful defense by the patent holder can delay it.
Key Takeaways
- US Patent 8,291,904 protects a specific method of treating major depressive disorder using vortioxetine within a daily dosage range of 5 mg to 20 mg.
- This patent is a method of use patent, distinct from the composition of matter patents that protect the vortioxetine molecule itself.
- The patent's exclusivity period, based on its issuance date and typical patent law, would have largely expired in the early to mid-2020s, subject to extensions and legal challenges.
- The broader patent landscape for vortioxetine, including numerous patents covering composition, use, and formulation, has been a critical factor in determining generic market entry timelines.
- Vortioxetine patents have been subject to significant litigation, with generic companies challenging patent validity and innovator companies defending their exclusivity, directly influencing competition.
FAQs
-
When did US Patent 8,291,904 officially expire?
The standard term for US Patent 8,291,904 would have expired approximately 20 years from its filing date, which, based on its issue date of October 18, 2012, would likely place its expiration in the early to mid-2020s, though actual market exclusivity depends on patent term extensions, adjustments, and litigation outcomes.
-
Can generic vortioxetine be prescribed for any dosage if patent 8,291,904 is expired?
Even if patent 8,291,904 has expired, other patents related to vortioxetine, such as those covering different dosages, formulations, or specific indications, may still be in effect, influencing the scope of what generic products can be marketed and for which uses.
-
What was the primary mechanism of action for vortioxetine as described in the patent?
The patent highlights vortioxetine's multimodal mechanism, acting as a serotonin reuptake inhibitor and a direct modulator of serotonin receptors including 5-HT1A, 5-HT1B, 5-HT3, 5-HT1D, and 5-HT7.
-
Did US Patent 8,291,904 cover the development of Trintellix/Brintellix?
Yes, US Patent 8,291,904 is a method of use patent that covers a key treatment regimen for vortioxetine, the active ingredient in Trintellix (US) and Brintellix (international).
-
What is the significance of a "method of use" patent compared to a "composition of matter" patent?
A "composition of matter" patent protects the drug molecule itself, preventing its synthesis or sale. A "method of use" patent protects a specific application or treatment protocol for that drug, preventing others from practicing that particular method even if the drug molecule is available.
Citations
[1] Lundbeck Research USA, Inc. (2012). United States Patent 8,291,904: Method of treating depression. U.S. Patent and Trademark Office.
[2] U.S. Food and Drug Administration. (n.d.). Orange Book. Retrieved from [FDA Orange Book Database] (Note: Specific database URL is dynamic and best accessed via FDA website).
[3] Hatch-Waxman Act, 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2012).
